Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance
Second-Quarter 2022 Results: — Net Sales of $876.4 Million; Orphan Segment Net Sales Increased 13% to $841.3 Million — — GAAP Net Income of $61.0 Million; Adjusted EBITDA of $306.6 Million — — TEPEZZA® (teprotumumab-trbw) Net Sales of $479.8 Million — — KRYSTEXXA® (pegloticase injection) Net Sales of $167.8 Million — — Cash Position of … [Read more…]
